Last updated: 1 September 2020 at 7:34pm EST

Capital Partners Iii, Llc L... Net Worth




The estimated Net Worth of Capital Partners Iii, Llc L... is at least 5.79 百万$ dollars as of 25 November 2019. Capital L owns over 937,000 units of Molecular Templates Inc stock worth over 5,751,993$ and over the last 6 years Capital sold MTEM stock worth over 37,582$.

Capital L MTEM stock SEC Form 4 insiders trading

Capital has made over 3 trades of the Molecular Templates Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Capital sold 3,496 units of MTEM stock worth 37,582$ on 28 August 2020.

The largest trade Capital's ever made was buying 937,000 units of Molecular Templates Inc stock on 25 November 2019 worth over 7,496,000$. On average, Capital trades about 326,374 units every 177 days since 2018. As of 25 November 2019 Capital still owns at least 4,198,535 units of Molecular Templates Inc stock.

You can see the complete history of Capital L stock trades at the bottom of the page.



What's Capital L's mailing address?

Capital's mailing address filed with the SEC is 2825 Sand Hill Rd, Menlo Park, CA 94025, USA.

Insiders trading at Molecular Templates Inc

Over the last 7 years, insiders at Molecular Templates Inc have traded over 22,993,582$ worth of Molecular Templates Inc stock and bought 14,744,530 units worth 82,519,716$ . The most active insiders traders include Target N Vbb Biotech Ag Bio...David HirschCapital Partners Iii, Llc L.... On average, Molecular Templates Inc executives and independent directors trade stock every 47 days with the average trade being worth of 532,718$. The most recent stock trade was executed by Target N Vbb Biotech Ag Bio... on 2 April 2024, trading 250,000 units of MTEM stock currently worth 587,500$.



What does Molecular Templates Inc do?

molecular templates (mtem) is a clinical-stage biopharmaceutical company targeting a variety of cancers through development of its innovative proprietary engineered toxin body (etb) platform. mtem’s first immunotoxin, mt-3724, is in clinical development for non-hodgkin’s lymphoma. pipeline products for additional oncology targets are being advanced toward clinical development. for more information, please visit mtem’s website at www.mtem.com.



Complete history of Capital L stock trades at Molecular Templates Inc

インサイダー
取引
取引
合計金額
Capital Partners Iii, Llc L...
販売 37,582$
28 Aug 2020
Capital Partners Iii, Llc L...
購入する 7,496,000$
25 Nov 2019
Capital Partners Iii, Llc L...
購入する 2,007,500$
21 Sep 2018


Molecular Templates Inc executives and stock owners

Molecular Templates Inc executives and other stock owners filed with the SEC include: